Human Urine-Derived Stem Cell Differentiation to Endothelial Cells with Barrier Function and Nitric Oxide Production

GUIHUA LIU, RONGPEI WU, BIN YANG, CHUNHUA DENG, XIONGBING LU, STEPHEN J. WALKER, PETER X. MA, STEVE MOU, ANTHONY ATALA, YUANYUAN ZHANG

ABSTRACT

Endothelial cells (ECs) play a key role in revascularization within regenerating tissue. Stem cells are often used as an alternative cell source when ECs are not available. Several cell types have been used to give rise to ECs, such as umbilical cord vessels, or differentiated from somatic stem cells, embryonic, or induced pluripotent stem cells. However, the latter carry the potential risk of chronic immune rejection and oncogenesis. Autologous endothelial precursors are an ideal resource, but currently require an invasive procedure to obtain them from the patient’s own blood vessels or bone marrow. Thus, the goal of this study was to determine whether urine-derived stem cells (USCs) could differentiate into functional ECs in vitro. Urine-derived cells were then differentiated into cells of the endothelial lineage using endothelial differentiation medium for 14 days. Changes in morphology and ultrastructure, and functional endothelial marker expression were assessed in the induced USCs in vitro. Grafts of the differentiated USCs were then subcutaneously injected into nude mice. Induced USCs expressed significantly higher levels of specific markers of ECs (CD31, vWF, eNOS) in vitro and in vivo, compared to nondifferentiated USCs. In addition, the differentiated USCs formed intricate tubular networks and presented similar tight junctions, and migration and invasion ability, as well as ability to produce nitric oxide (NO) compared to controls. Using USCs as autologous EC sources for vessel, tissue engineering strategies can yield a sufficient number of cells via a noninvasive, simple, and low-cost method suitable for rapid clinical translation.

SIGNIFICANCE STATEMENT

The present study demonstrated that urine-derived stem cells (USCs) possess endothelial differentiation potential in vitro and after implantation in vivo. These induced USCs displayed biological characteristics of endothelial cells (ECs), including endothelial marker expression, low-density lipoprotein (LDL) uptake, network formation, permeability prevention, tight junction structure, migration and invasion ability, secretion of angiogenic factors, and NO production. Moreover, EC-induced autologous USCs gave rise to ECs in vivo, indicating that USCs may be a good candidate cell source for tissue-engineered vascular regeneration or repair of endothelial dysfunction.

INTRODUCTION

The current solution to the requirement for long-term blood vessel revascularization is surgery using coronary artery or peripheral artery bypass grafts. At present, autologous vessels (e.g., left internal mammary and radial arteries or the greater saphenous vein) are used as implants for small/middle-diameter vessels. These autologous vessels are of limited availability, require invasive harvest, and are often unsuitable for use. Use of allogenic grafts (such as cryopreserved cadaveric vessels and umbilical vein grafts) is not optimal due to risk of thrombosis, intimal hyperplasia, atherosclerosis, and infection. Synthetic vascular grafts have demonstrated reasonable long-term outcomes when used in large or medium-diameter arteries, but have had limited success in small-diameter vessels because of unsatisfactory patency rates. A tissue-engineered vascular graft using autologous cells and suitable scaffolds would be an attractive alternative to improve revascularization approaches.

Although immortalized endothelial cells (ECs) are commercially available and have a long life span, these cells are often not used for various
tissue regeneration purposes due to significant safety concerns. The primary cells are more biologically relevant tools than cell lines for tissue repair or tissue repair [1]. Three types of vascular cells—ECs, smooth muscle cells, and fibroblasts—have been used to create tissue-engineered vessels. For EC preparation for engineered vessels, several different cell types have been used, both autologous and allogeneic. ECs or progenitor cells such as human umbilical cord endothelial cells (HUCs) are most commonly used. In addition, adult stem cells such as bone marrow-derived mesenchymal stromal cells [2], muscle-derived progenitor cells [3], and adipose-derived stem cells [4], are candidate alternative cell sources for endothelial lineage differentiation. Furthermore, ESCs and induced pluripotent stem cells (iPSCs) [5, 6] have successfully been differentiated into ECs. Nonetheless, the limited quantity and donor site morbidity of somatic ECs, risk of oncogenesis from iPSCs, and ethical issues surrounding use of ESCs have hindered their extension to clinical application. In addition, most of those stem cells are from allogeneic sources, which can cause chronic rejection and thrombosis. Thus, an alternative autologous stem cell source obtained with noninvasive procedures would be desirable.

Recently, we have successfully established a primary culture system to isolate stem cells from urine (urine-derived stem cells [USCs]). These cells possess the desired regenerative properties, including robust proliferative potential, multipotential differentiation, and paracrine effects [7–9]. USCs secrete multiple trophic factors to recruit resident cells to participate in tissue regeneration and induce immune-modulatory changes to reduce inflammatory and fibrosis in vivo [7, 10, 11]. In addition, USCs can be obtained noninvasively at a low cost, using a simple technology to harvest good-quality cells that can be expanded to the required quantity [12]. The purpose of this study was to demonstrate that USCs can give rise to ECs, which could potentially provide a robust autologous cell source for angiogenesis and vascular tissue engineering.

**MATERIALS AND METHODS**

**Ethical Approval**

The protocol for collection of human urine samples from healthy donors was approved by the Wake Forest University Health Sciences (WFUHS) Institutional Review Board. The study protocol conforms to the ethical guidelines of Declaration of Helsinki. Written informed consent was obtained from the urine donors. Experiments in nude mice were approved by the Institutional Animal Care and Use Committee at WFUHS. All the animal experiments were conducted per NIH guidelines (Guide for the care and use of laboratory animals).

**Cell Isolation and Expansion**

Thirty-two voided urine samples (80–400 ml) from six healthy men (28–55 years old) were collected and cultured, as reported previously [12]. Briefly, after collection, sterile urine samples were centrifuged at 1,500 rpm for 5 minutes and the urine supernatant was discarded. The cell pellet was gently suspended in USC culture medium including equal volumes of embryo fibroblast medium (containing 1/3 Dulbecco’s modified Eagle’s medium, 1/3 Hamm’s F12, 10% fetal bovine serum [FBS], 0.4 μg/ml hydrocortisone, 10⁻¹⁰ M cholera toxin, 5 ng/ml insulin, 1.8 × 10⁻⁷ M adenosine, 5 μg/ml transferrin, 2 × 10⁻⁹ M 3,3’,5-triiodo-L-thyronine, 10 ng/ml epidermal growth factor. Sigma, St.Louis, MO) and keratinocyte serum-free medium (KSF, Invitrogen, Waltham, MA) containing 2% FBS, and then plated in 24-well plates at 37°C in a 20% O₂/5% CO₂ cell incubator. This was considered as passage 0 (p0). Individual clones appeared 3–5 days after being plated. Each single cell clone per well from a single cell was trypsinized. When cells reached a confluence of 60%–70%, they were transferred into 6-well plates (p1). Finally, USCs were transferred to a 150 mm culture dish (p2) for expansion. For most experiments, USCs at p3–4 were used.

**Flow Cytometry**

To evaluate the ability to stain surface markers, cultured USC (p2) were stained with specific anti-human antibodies labeled for CD24-FITC, CD29-FITC, CD44-FITC CD73-PE, CD90-PE, CD105-PerCP-Cy5.5, CD146-PE, CD140b, NG2, CD31-PE, CD34-PE, and CD45-FITC (Supporting Information Table S1). Briefly, following trypsinization, cells (5 × 10⁵) were resuspended in ice-cold phosphate buffered saline (PBS) containing 1% bovine serum albumin (BSA). Fluorochrome-conjugated antibodies were added to cells in 50 ml PBS containing 3% BSA and incubated. IgG1-PE, IgG1-FITC, IgG2b-FITC, and IgG1-PerCP-Cy5.5 conjugated isotype control antibodies were used to determine background fluorescence. Cells were then washed twice in wash buffer, passed through a 70-μm filter, and analyzed by flow cytometry (FACS Calibur BD Biosciences, Franklin Lakes, NJ).

**Endothelial Differentiation of USCs**

USCs at p3 were plated on fibronectin (Millipore, Billerica, MA) coated 6-well plates at a density of 3,000 cells/cm², allowed to attach for 24 hours in the Dulbecco’s Modified Eagle Medium (DMEM) with 10% FBS, then cultured in Endothelial Growth Media 2 (EGM-2; Lonza Biologics, Portsmouth, NH) in 2% FBS with a fresh mix of 50 ng/ml Vascular endothelial growth factor(VEGF) (PeproTech, Rocky Hill, NJ). ECs induced from USCs (EC-induced USCs) were characterized 14 days after being cultured in EGM-2 media. As a positive control, HUVECs (BD Bioscience, San Jose, CA) were cultured on fibronectin-coated plates (Millipore, Billerica, MA) in EGM-2, while noninduced USCs (p3) in DMEM with 10% FBS were used as a negative control through all the experiments described below. To obtain pure ECs, induced USCs were sorted with fluorescence-activated cell sorting (FACS) with CD 31 antibody.

To evaluate the roles of the classic regulation pathways [13] (phosphatidylinositol-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways) of endothelial differentiation when USCs induced into ECs, the PI3K inhibitor LY294002 (Sigma, St. Louis, MO) and MAPK inhibitor PD98059 (Sigma, St. Louis, MO) were added to the EGM-2, each at a final concentration of 15 μM.

**Immunohistochemistry**

Cultured cells were fixed with prechilled acetone for 15–30 minutes at −20°C, blocked with serum-free block solution (Dako, Glostrup, Denmark) for 15 minutes at room temperature, and incubated with endothelial-specific and tight junction antibodies overnight at 4°C, with secondary antibodies (1:200; Vector Laboratories, Burlingame, CA) for 1 hour at room temperature (antibodies listed in Supporting Information Table S1). Cells were then counterstained with anti-fade mounting media containing propidium iodide (Vector Laboratories, Burlingame, CA). Cell morphology was imaged with a phase contrast microscope (Zeiss, Oberkochen, Germany) and a Leica upright fluorescence microscope (DM 4000B, Buffalo Grove, IL) using Image J software.
Real-Time Polymerase Chain Reaction (PCR)

EC-specific messenger RNA levels were quantified by real-time PCR analysis. Briefly, total RNA was extracted using an RNA isolation kit (5 PRIME, Gaithersburg, MD) according to the manufacturer’s instructions. Five microgram of RNA was converted to cDNA in a reaction containing random primers, nucleotides, and reverse transcriptase enzyme by using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). One-tenth of the cDNA was then used for real-time PCR assay using Taqman Universal PCR master mix and Taqman gene expression probes (vWF, Hs00169795_m1; CD31, Hs01065279_m1; GAPDH, NM_002046.3; Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions on a 7300 Real-Time PCR System (Applied Biosystems).

Western Blot

Endothelially induced USCs were harvested from each 10 cm culture dish and the proteins were extracted using RIPA lysis buffer (Thermo Scientific, Waltham, MA) containing a proteinase inhibitor cocktail (Roche Applied Sciences, Upper Bavaria, Germany). Protein extracts (15–30 μg) were run on 6%–10% sodium dodecyl sulfate-polyacrylamide gels to separate the proteins. A prestained protein ladder (Benchmark, Invitrogen, Waltham, MA) was used to monitor resolution of protein bands. After electrophoresis, the separated proteins were transferred to a polyvinylidene fluoride membrane (Millipore, Billerica, MA) by semi-dry transfer. Following transfer, the membrane was incubated in blocking solution (5% nonfat dry milk in PBS) for 1 hour at room temperature. For protein signal analysis, the membrane was incubated overnight at 4°C with primary antibodies (Supporting Information Table S1) in 1% milk, subsequently washed with 0.05% Tween in PBS and then incubated with the appropriate diluted horseradish peroxidase (HRP)-conjugated secondary antibody for 1 hour at room temperature. The blots were visualized with an enhanced chemiluminescence detection system by an enhanced chemiluminescence assay (Supersignal West Femto, Thermo Scientific).

Functional Analysis of Differentiated USCs

Tube Formation on Matrigel. The network formation ability of EC-induced USCs was assessed by using growth factor-reduced Matrigel (BD Pharmingen, San Jose, CA) according to the manufacturer’s instructions. Briefly, Matrigel was thawed at 37°C overnight and used to coat culture plates at 50 μl/cm². The coated plates were then incubated at 37°C for at least 30 minutes to allow for solidification. Induced USCs were trypsinized and seeded on Matrigel at 7,500 cells/cm² and cultured in EGM-2 supplemented with 50 ng/ml VEGF for 14 days, incubated at 37°C, with 5% CO₂. After 24 hours of incubation, cells in plates were labeled with 8 μg/ml Calcein AM fluorescent dye (BD Pharmingen, San Jose, CA) following the manufacturer’s instructions. Formation of cord-like structures was observed by phase-contrast and inverted immunofluorescent microscopy (Leica) and tube area was calculated by ImagePro software (version 6.3).

Acetylated Low-Density Lipoprotein Uptake. To assess acetylated low-density lipoprotein (ac-LDL) uptake, EC-induced USCs were incubated with Alexa Fluor 488-labeled ac-LDL (Invitrogen, Waltham, MA) at 37°C for 4 hours at a concentration of 10 μg/ml, then fixed with 4% paraformaldehyde and counterstained with 4’,6-diamidino-2-phenylindole (DAPI). For statistical analysis, 10 separate fields were viewed with an immunofluorescence microscope under ×200 to determine uptake of Alexa Fluor 488-labeled labeled ac-LDL. The ratio of positive cells/total DAPI was calculated as a positive ratio.

In Vitro Vascular Permeability Assay. To detect endothelial permeability of EC-induced USCs, confluent cells were assessed by In Vitro Vascular Permeability Kits (Millipore, Billerica, MA) following the manufacturer’s instructions. Briefly, cells (2.5 × 10⁵) were seeded into the inserts precoated with type I rat-tail collagen after hydration and then incubated in a 37°C, 5% CO₂ cell culture incubator for 72 hours. Trace-containing phenol-free medium (FITC-Dextran, 150 μl) was changed in the insert (top chamber) and 0.5 ml tracer-free medium was added in the bottom well. The plate was then incubated, protected from light, for 20 minutes at room temperature. Media aliquots (100 μl) were removed from the bottom chamber for fluorescence measurements (excitation at 485 nm and emission at 535 nm) after 3 hours. Diffusion of these dyes through a nude insert membrane served as an internal control. Permeability prevention ability was determined by comparing the leakage of fluorescent dextran across the EC-induced USCs monolayer compared to controls including no cells, USCs, or HUVECs. Leakage was calculated by measuring the fluorescent intensity of FITC-dextran in the basolateral chamber.

Ultrastructure of Tight Junctions. Transmission electron microscopy (TEM) studies were used to visualize the presence of tight junctions in EC-induced USCs. The cells were cultured and induced on 6-well plates trans-well inserts, fixed, and sectioned according to standard TEM protocols [14]. Briefly, the cultured cells were fixed in 2.5% glutaraldehyde, postfixed with 1% osmium tetroxide, dehydrated in graded alcohols, embedded in Spurr’s resin (Polysciences, Warrington, PA), and cut into 80-nm sections with a Reichert Ultracut E ultra-microtome. The specimens were viewed and photographed with a Tecnai Spirit BioTwin transmission electron microscope (FEI, Hillsboro, OR) equipped with an AMT 12 megapixel 2Vu camera (Woburn, MA).

Invasion Capability. The invasion capability of EC-induced USCs was performed by the BioCoat Angiogenesis System, an EC invasion kits (BD Pharmingen, San Jose, CA) following the manufacturer’s instructions. Briefly, after collected and suspended in serum free culture medium, cells (5 × 10⁵/250 μl) were seeded on the top insert coated with BD Matrigel Matrix. Culture medium (750 μl) containing 5% FBS and VEGF (10 ng/ml) was then added as a chemoattractant to each of the bottom wells. The cells seeded on the uncoated insert plate were used as a negative control. Following incubation for 22 ± 1 hours in standard culture conditions (37°C, 5% CO₂), the insert plate was transferred into a second 24-well plate containing 4 μg/ml calcein AM (0.5 ml/well, BD Pharmingen, San Jose, CA) in Hank’s Balanced Salt Solution and incubated for an additional 90 minutes. Fluorescence of stained invaded cells was measured in a spectrophotometer (Molecular Devices, Inc., Sunnyvale, CA) at excitation/emission wavelengths of 494/517 nm. The percentage of invasion was calculated using the following formula:

\[
% \text{Invasion} = \left( \frac{\text{Mean relative fluorescence units [RFU] of cells invading through membrane}}{\text{Mean RFU of cells migrating through control insert}} \right) \times 100
\]
**Cellular Migration Ability Assay.** The migration ability of EC-induced USCs was measured by EC migration kits (BioCoat Angiogenesis System, BD Pharmingen) following the manufacturer’s instructions. Briefly, all the cells were cultured overnight in basal medium (lacking serum or growth supplements) supplemented with 0.1% BSA. After harvest and resuspension in serum-free culture medium, cells (3 × 10^5 cells/750 μl) were seeded on the top of each human fibronectin-coated migration chamber with a polycarbonate membrane (3 μm pore size). Culture medium (750 μl, with 5% FBS and VEGF 10 ng/ml) was immediately added as a chemoattractant to the bottom wells. Serum-free culture medium without chemoattractant served as a negative control.

Following incubation for 22 ± 1 hours in standard culture conditions (37°C, 5% CO₂), the insert plate was transferred into a second 24-well plate containing 4 μg/ml calcein AM (0.5 ml/well, BD Pharmingen), a cell-permeant dye, in Hank’s Balanced Salt Solution and incubated for 90 minutes. Fluorescence of stained migrated cells was read in a spectrophotometer ( Molecular Devices, Inc., Sunnyvale, CA) at excitation/emission wavelengths of 494/517 nm. The fold migration was calculated using the following formula:

\[
\text{Fold Migration} = \frac{\text{Mean RFU of inserts with cells migrating toward chemoattractant}}{\text{Mean RFU of cells migrating without chemoattractant}}
\]

**Nitric Oxide Secretion.** Nitric oxide (NO) secretion by EC-induced USCs was detected with the Measure-IT High-Sensitivity Nitrite Assay Kit (Invitrogen) according to manufacturer’s instructions. Briefly, the total NO produced by induced USCs was assayed in the form of nitrites after conversion of nitrates via nitrate reductase. Total nitrite levels for EC-induced USCs were calculated based on a nitrite calibration curve, and then normalized to total protein levels.

**Secreted Trophic Factors.** EC-induced USC (5 × 10^5, p2) were seeded in each well of 6-well plates and incubated with serum-free DMEM under normal culture conditions (5% CO₂, 37°C) for 24 hours. The conditioned medium from cultured cells was collected and analyzed with a human angiogenesis array kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. Briefly, the membrane containing antibodies specific to 55 specific angiogenesis-related proteins was blocked with BSA for 1 hour on a rocking platform at room temperature. The membrane was then incubated with DMEM only or cell culture supernatants along with detection antibody cocktail overnight on a rocking platform at 4°C. The membrane was incubated with streptavidin-horseradish peroxidase conjugate antibody and developed on x-ray film following exposure to chemiluminescent reagents. Pixel density was determined using Quantity One software and normalized to mean pixel density from reference spots on the same membrane.

**In Vivo Studies**

To evaluate endothelial differentiation and angiogenesis of USC in vivo, USC incubated in collagen I gel with or without VEGF-enveloped alginic microbeads were subcutaneously injected into nude mice (four sites per mice, two mice per group) [10]. When the cells were injected, all the mice were anesthetized with isoflurane by air in approved anesthetic chamber (initial dose was 3%–5% and additional maintenance dose was 1%–3%). At 4 weeks, after the mice were sacrificed with CO₂ asphyxiation followed by a cervical dislocation, the implants were harvested and then fixed in 4% paraformaldehyde, and then embedded in paraffin. To track endothelial differentiation of the implanted USC, slides of grafted tissues (5 μm) were assessed with immunofluorescent triple staining using DAPI combined human nuclei antigen (Millipore) and endothelial-specific markers (CD31 and vWF) antibodies. Histologic slides were visualized under a Leica-DM4000B fluorescent microscope and images were recorded for analysis.

**Statistical Analyses**

Values are expressed as mean ± SD. One-way Analysis of variance (ANOVA) followed by a Student-Newman-Keuls post hoc test for multiple comparisons were used when appropriate. SPSS16.0 software was used for analyses. p ≤ .05 was considered as statistically significant.

**Results**

**Characterization of USCs**

USCs displayed a rice-grain-like appearance 2–3 days after initial seeding. These cells further formed clones within an additional 4–6 days. FACS analysis showed that USCs consistently expressed somatic stem cell surface markers (CD24, CD29, CD44, CD73, CD90, CD105), but neither hematopoietic stem cell markers (CD34, CD45) nor EC markers (CD31) (Supporting Information Fig. S1). Over 90% of USCs expressed pericyte markers (CD146, Supporting Information Fig. S1). However, a few USCs expressed NG2 and PDGF-Rβ.

**Functionality of EC-Induced USCs**

**EC-Induced USCs Expressed EC-Specific Markers.** Real-time PCR quantitative analysis revealed that EC-induced USCs expressed endothelial-specific gene-CD31 and vWF (Fig. 1A). Immunofluorescent staining and Western blot analysis showed that EC-induced USCs expressed CD31, vWF, and eNOS protein markers, compared to negligible expression seen in USC (Fig. 1B–1D). EC-induced USCs expressed significantly higher levels of basal NO radicals (pg/10^6 cells) over 48 hours across all VEGF incubation concentrations (n = 10; 56.2 ± 2.1) than USCs (8 ± 0.02; p < .001) and HUVECs (control; 194.7 ± 8.9) (Fig. 1E).

In addition, numbers of EC-induced USCs expressing endothelial markers (CD31/eNOS) increased with increasing differentiation time, that is, 0.9%/0.6% on day 0, 19%/13% on day 7, 23%/16% on day 14, and 29%/23% on day 28 after differentiation (Fig. 1F). After cell sorting based on CD31 antibody by using FACS, up to 99% of the EC-induced USCs expressed CD31. Inhibition of the PI3K pathway significantly reduced mRNA and protein expression of CD31 and von Willebrand factor in EC-induced USCs (Fig. 1A, 1D). These effects were not seen with inhibition of the MAPK pathway.

**EC-Induced USCs Formed Tube Networks on Matrigel.** The ability to form vascular-tube-like networks was assessed by plating undifferentiated USCs, differentiated USCs cultured in EGM-2 containing 50 ng/ml VEGF, and HUVECs on Matrigel thin films. Few undifferentiated USCs showed network formation, and the vast majority of the cells maintained a rounded morphology. After differentiation, significantly more EC-induced USCs formed networks,
EC-Induced USCs Uptake of AF488-Conjugated ac-LDL. Most EC-induced USCs showed significantly increased levels of ac-LDL uptake ($n = 10$ separate fields under $\times 200$ magnification; 72.3% ± 6.8%), compared to USCs ($n = 10$ frames; 3.1% ± 1.7%) ($p < .001$) and HUVECs as a standard control (93% ± 2.8%) (Fig. 3).

Permeability Barrier Function and Structure of EC-Induced USCs. Immunofluorescent staining and Western blot analysis demonstrated that tight junction proteins (ZO-1, occluding, and E-cadherin) significantly increased in EC-induced USCs (Fig. 4A–4D).
The permeability of EC-induced USCs monolayers significantly decreased to 21.4% by 2 weeks after differentiation, compared to USCs (58.5%) and HUVECs as a positive control (9.6%) (for all, \( p < .01 \)) (Fig. 4E). In addition, examination by TEM showed an ultrastructure indicative of tight junction formation between neighboring cells in HUVECs and EC-induced USCs, but not in USCs (Fig. 4F).

**Invasion and Migration Ability of EC-Induced USCs.** The invasion rate of EC-induced USCs was significantly higher than that of USCs (38.2\% \pm 2.1\% vs. 25.1\% \pm 3.1\%, \( p < .05 \)) with HUVECs used as a standard (51.2\% \pm 9.8\%, \( p < .01 \)) (Fig. 5A). The fold migration of EC-induced USC (3.9 \pm 0.6) was significantly higher than USCs (1.8 \pm 0.1, \( p < .05 \)) and HUVECs (positive control; 20.7 \pm 1.7, \( p < .01 \)) (Fig. 5B). The invasion capability of EC-induced USCs was in consistent with results of the cell migration assay.

**Secretion of Angiogenic Trophic Factors.** Seventeen angiogenesis-related proteins (e.g., angiogenin, endostatin, endothelin-1, MMP-9, CXCL16, and VEGF) were detected in the supernatant of USCs, EC-induced USCs, and HUVECs, as shown in Figure 6. These results indicate no significant changes in angiogenic trophic factors in USCs after endothelial induction.

**In Vivo Angiogenic Differentiation**

In noninduced USCs grafts, immunofluorescent triple staining demonstrated that a few cells expressed EC markers (CD31 and vWF) and human nuclei markers 4 weeks after subcutaneous implantation in vivo. In contrast, numbers of cells expressing these markers significantly increased in EC-induced USCs graft tissue with VEGF alginate microbeads, compared to the USCs groups (\( p < .05 \)) (Fig. 7).

**DISCUSSION**

The present study demonstrated that USCs possess endothelial differentiation potential in vitro and after implantation in vivo. These induced USCs displayed biological characteristics of ECs, including endothelial marker expression, LDL uptake, network formation, permeability prevention, tight junction structure, migration and invasion ability, secretion of angiogenic factors, and NO...
production. Moreover, EC-induced autologous USCs gave rise to ECs in vivo, indicating that USCs may act as a good candidate cell source for tissue-engineered vascular regeneration or repair of endothelial dysfunction.

ECs are specialized to acquire blood-forming hemogenic phenotypes and functions during the vascular remodeling process in tissue-engineered vessels. ECs form the inner lining of a blood vessel but also possess multifunctional paracrine and endocrine effects. They provide an anticoagulant barrier between the vessel wall and blood, which is vital in vasculogenesis and revascularization. EC dysfunction, injury, or activation occur in many pathophysiologic states, including atherosclerosis, loss of semipermeable membrane function, and thrombosis. Several types of stem cells have been used for vascular regeneration [15] when ECs were not available. Although several types of stem cells (including ESCs, iPSCs, and somatic stem cells) have been reported to give rise to ECs, their use comes with ethical concerns, tumor risk, vascular instability, or limited proliferative potential.

USC possess biological properties of stem cells, including clonogenicity, robust expansion capacity, multipotent differentiation capacity [16–18], and trophic factor secretion [19]. These cells, originating from the parietal cells in kidney glomeruli [7], can be obtained using noninvasive, simple, safe, and low-cost procedures, avoiding adverse events associated with current therapies. USCs can be easily isolated and expanded [7, 17, 20], which offers clear advantages over stem cells from other sources [21]. After optimizing our methods, 100–140 USC clones/24 hours urine collection were consistently obtained from each individual [20]. These cells can generate a large number of cells from a single clone [22], as USCs expressed telomerase activity (USCs-TA+) and retained long telomere length [23]. Importantly, they retain chromosomal stability over long time passages in vitro [12]. Isolation of USCs does not require tissue dissociation procedures, cell viability is better protected, since no digestive enzymes are involved [17, 20]. Our recent data and results from other investigators demonstrated that USCs have optimal regenerative potential for regeneration of bladder [24], kidney [25–27], corpora cavernosa [10, 28], bone [29–32], lungs [33], skin [34], nerve [35], and other types of tissue [30, 32, 34, 36–41]. These cells are safe to use in vivo without any risk of oncogenicity [7, 28, 42]. Thus, USCs could
Figure 2. Acquisition of EC-induced USCs. (A): EC-differentiated USCs displayed cuboidal cobblestone monolayer morphology under phase contrast microscopy; (B, C) EC differentiated USCs formed capillary-like structures, similar to HUVEC 24 hours after plating onto Matrigel. When exposed to the PI3K inhibitor LY294002, induced USCs failed to form capillary structure, but no inhibition effect was seen with mitogen-activated protein kinase inhibitor PD98059 on induced USCs. Scale bar = 50 μm. Abbreviations: EC, endothelial cell; HUVEC, human umbilical cord endothelial cell; USCs, urine-derived stem cells.

Figure 3. Acetylated low-density lipoprotein uptake of EC-differentiated USCs. EC-induced USCs significantly increased metabolizing ac-LDL uptake (green), compared to USCs (n = 10; *, p < .05; **, p < .01). Nuclei counterstained with DAPI (blue). Scale bar = 50 μm. Abbreviations: ac-LDL, acetylated low-density lipoprotein; DAPI, 4',6-diamidino-2-phenylindole; EC, endothelial cell; HUVECs, human umbilical cord endothelial cells; USCs, urine-derived stem cells.
Figure 4. Tight junction formation of EC-induced USCs. Endothelially induced USCs expressed tight junction markers (E-cadherin, occludin, and ZO-1) confirmed by immunofluorescent staining (A, B) and Western blots (C, D). Permeability of EC-induced USCs significantly increased, compared to USCs (E). *, p < .05; **, p < .01. Desmosomes were observed in EC-induced USCs and HUVECs (white arrows) but not in USCs (F). Scale bar = 100 nm. Abbreviations: DAPI, 4',6-diamidino-2-phenylindole; endothelial cell; HUVECs, human umbilical cord endothelial cells; USCs, urine-derived stem cells.

© 2018 The Authors STEM CELLS TRANSLATIONAL MEDICINE published by STEM CELLS TRANSLATIONAL MEDICINE Wiley Periodicals, Inc. on behalf of AlphaMed Press
The efficiency of endothelial differentiation is an important consideration if stem cells are to provide a sufficient number of ECs for tissue-engineered vessels and cell therapy. ESCs possessed the most efficient endothelial differentiation, reaching 50%–81.6% [43, 44], while only about 18% of mesenchymal stem cells could be induced to an endothelial phenotype [45]. In the present study, one-third of USC clones were able to give rise to ECs after induction. After cell sorting, pure EC population can be obtained from the induced USCs. These USCs efficiently differentiated into ECs with endothelial markers (i.e., CD31, vWF, eNOS), and displayed barrier function and tight junction formation in vitro. In addition, USCs efficiently differentiated into ECs in vivo induced by VEGF released from alginate beads. VEGF also improved cell survival of the implanted USC.

Results from this study showed that capillary formation and CD31 and von Willebrand factor expression in EC-induced USCs can be inhibited by inhibitors of the PI3K pathway but not MAPK pathway, suggesting that endothelial differentiation of USCs depends on the PI3K pathway. This finding is consistent with other studies [13] which reported the PI3K pathway regulated endothelial differentiation of adipose-derived stem cells.

Endothelial NO synthase plays an important role in vasodilation and vasoconstriction to control blood pressure when ECs respond to various stimuli, including circulating lipoproteins, growth factors, and changes in hemodynamic mechanical forces. In pathophysiological conditions, reduced NO bioavailability is a key factor in the development and progression of endothelial dysfunction. Therefore, autologous EC-induced USCs can be used for either vessel reconstruction with tissue engineering technology, or endothelial dysfunction modeling to study vascular diseases. Our data demonstrated that about 25% of USCs expressed eNOS after endothelial differentiation, indicating that a subset of EC-induced USCs can produce functional eNOS for NO production, similar to native ECs.

The endothelium acts as a semi-selective impediment between the vessel lumen and surrounding tissue, controlling the travel of various biomaterials and the transport of white blood cells into and out of the bloodstream. EC barrier permeability is a

Figure 4. (Continued).

![Image](image-url)

Figure 5. Invasion and migration of endothelially induced USCs. Induced USCs displayed significantly increased invasion (A) and migration (B), compared to USCs. Fold migration = Mean relative fluorescence units (RFU) of inserts with cells migrating through membrane toward chemoattractant (EGM-2 containing 10 ng/ml VEGF)/ Mean RFU of cells migrating through membrane without chemoattractant. % invasion = (Mean RFU of cells invading through BD Matrigel Matrecoated BD FluoroBlok membrane/ Mean RFU of cells migrating through uncoated BD FluoroBlok control insert). *, p < .05; **, p < .01. Abbreviations: VEGF, vascular endothelial growth factor; EC, endothelial cell; HUVECs, human umbilical cord endothelial cells; USCs, urine-derived stem cells.

www.StemCellsTM.com © 2018 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
key factor for tissue-engineered vessels. In our study, EC-induced USCs and HUVECs (used as controls) possessed similar tight junction function, including leakage prevention, tight junction markers, and desmosomes, indicating that a subset of EC-induced USCs behaved like mature ECs.

Cellular functions (including ingrowth, migration, invasion, and sprouting of ECs) are pivotal for new vessel formation or angiogenesis. We found that EC-induced USCs possessed migration and invasion abilities similar to mature HUVECs. The cell invasion assay we used is closely related to the transwell migration assay, but responds to a different set of requests. Whereas the transwell migration assay measures the number of cells passing through a porous membrane, the cell invasion assay focuses on invasive cell migration via an extracellular matrix. Invasive migration is a key process in angiogenesis and in tissue repair processes. Our data also demonstrated that ECs possess “scavenger” receptors specific for the modified LDL when the LDL’s apoproteins have been acetylated. This acetylation decouples the LDL complex’s binding to the LDL receptor, indicating that EC-induced USCs can uptake ac-LDL to normalize function of the LDL complex.

We further demonstrated in the present study that USCs secreted a series of angiogenic trophic factors and cytokines. Single angiogenic growth factors to augment neovascularization in patients have only showed limited success to date [46]. One possible reason for this may be that angiogenesis requires multiple growth factors acting in concert [47]. Angiogenic and antiapoptotic growth factors (e.g., VEGF and hepatocyte growth factor) acting synergistically [48] were secreted by USCs in our study. In addition, these
factors once released may themselves have autocrine actions on the biology of stem cells, enabling them surviving longer in vivo [49]. Therefore, even though only one quarter of USCs could be induced mature ECs, USCs are good cell sources for the angiogenesis therapy because uninduced USCs also can secrete angiogenic growth factors.

**CONCLUSION**

EC-induced USCs were functionally and morphologically similar to HUVECs. An advantage of using USCs as an autologous EC source for tissue-engineered vessels, angiogenesis, and repair of endothelial dysfunction modeling is that these methods may yield a sufficient number of cells via a noninvasive method that would be suitable for rapid clinical translation.

**ACKNOWLEDGMENTS**

We acknowledge funding support from NIH Grant R56 DK100669 (Y. Zhang), Natural Science Foundation of China (Grant 81371704, 81401197, 81671834, 81471449, 81671449 and 81570650), Science and Technology Planning Project of Guangdong Province (2016B030230001) and Key Scientific and Technological Program of Guangzhou City (201604020189). We also acknowledge the editorial assistance of Karen Klein, MA, in the Wake Forest Clinical and Translational Science Institute (UL1 TR001420; PI: McClain).

**DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST**

The authors indicated no potential conflicts of interest.

**REFERENCES**

1. Chong MS, Ng WK, Chan JK. Concise review: Endothelial progenitor cells in regenerative medicine: Applications and challenges. Stem Cells Translational Medicine 2016;5:530–538.
2. Kinebuchi Y, Aizawa N, Imamura T et al. Autologous bone-marrow-derived mesenchymal stem cell transplantation into injured rat urethral sphincter. Int J Urol 2010;17:359–368.
3. Chermansky CJ, Tarin T, Kwon DD et al. Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency. Urology 2004;63:780–785.
4. Lin G, Wang G, Banie L et al. Treatment of stress urinary incontinence with adipose tissue-derived stem cells. Cytotherapy 2010;12:88–95.
5. Narmada BC, Goh YT, Li H et al. Human stem cell-derived endothelial-hepatic platform for efficacy testing of vascular-protective metabolites from nutraceuticals. Stem Cells Translational Medicine 2017;6:851–863.
6. Giordano S, Zhao X, Chen YF et al. Induced pluripotent stem cell-derived endothelial cells overexpressing interleukin-8 receptors A/B and/or C-C chemokine receptors 2/5 inhibit vascular injury response. Stem Cells Translational Medicine 2017;6:1168–1177.
7. Bharadwaj S, Liu G, Shi Y et al. Multipotent differentiation of human urine-derived stem cells: Potential for therapeutic applications in urology. Stem Cells 2013;31:1840–1856.

Figure 7. Endothelial differentiation of USCs in vivo. (A): Implanted human USCs were by immunofluorescent labeling using human-specific nuclear mitotic apparatus antibody (stained in red). Specific staining appears reddish-purple (arrows) due to colocalization with DAPI (blue) stained nucleus. Scale bar = 50 μm. (B): Numbers of implanted USCs expressing HLA and endothelial cell markers significantly increased in implanted grafts of USCs + VEGF-microbeads, compared to those in USCs-alone graft tissue, assessed by semi-quantitative analyses of triple staining (CD31, vWF and HLA nuclei/DAPI staining, n = 10 frames). **, p < .01. Abbreviations: DAPI, 4',6-diamidino-2-phenylindole; USCs, urine-derived stem cells; VEGF, vascular endothelial growth factor.
cells in terms of cell proliferation, immune modulation and multi differentiation. J Korean Med Sci 2015;30:1764–1776.
22 Bodin A, Bharadwaj S, Wu S et al. Tissue-engineered conduit using urine-derived stem cells seeded bacterial cellulose polymer in urinary reconstruction and diversion. Biomaterials 2010;31:8889–8901.
23 Shi Y, Liu G, Bharadwaj S J et al. Urine derived stem cells with high telomerase activity for cell based therapy in urology. J Urol 2012;187:e302.
24 Lee JN, Chun SY, Lee HJ et al. Human urine-derived stem cells seeded surface modified composite scaffold gl ashes for bladder reconstruction in a rat model. J Korean Med Sci 2015;30:1754–1763.
25 Jiang ZZ, Liu YM, Niu X et al. Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type I diabetes in rats. Stem Cell Res Ther 2016;7:24.
26 Oliveira Arcolino F, Tort Piella A, Papadimitriou E et al. Human urine as a noninvasive source of kidney cells. Stem Cells Int 2015;2015:362562.
27 Laazeri E, Ronconi E, Angelotti ML et al. Human urine-derived renal progenitors for personalized modeling of genetic kidney disorders. J Am Soc Nephrol 2015;26:1961–1974.
28 Ouyang B, Sun X, Han D et al. Human urine-derived stem cells alone or genetically modified with FGFR2 improve type 2 diabetic erectile dysfunction in a rat model. PLoS One 2014;9:e92825.
29 Guan J, Zhang J, Li H et al. Human urine-derived stem cells in combination with beta-TCP can be applied for bone regeneration. PLoS One 2015;10:e0125253.
30 Guan J, Zhang J, Zhu Z et al. Bone morphogenetic protein 2 gene transduction enhances the osteogenic potential of human urine-derived stem cells. Stem Cell Res Ther 2015;6:5.
31 Guan J, Zhang J, Guo S et al. Human urine-derived stem cells can be induced into osteogenic lineage by silicate bioceramics via activation of the Wnt/beta-catenin signaling pathway. Biomaterials 2015;55:1–11.
32 Qin H, Zhu C, An Z et al. Silver nanoparticles promotes osteogenic differentiation of human urine-derived stem cells at noncytotoxic concentrations. Int J Nanomed 2014;9:2469–2478.
33 Wang C, Hei F, Ju Z et al. Differentiation of urine-derived human induced pluripotent stem cells to alveolar type II epithelial cells. Cell Reprogram 2016;18:30–36.
34 Fu Y, Guan J, Guo S et al. Human urine-derived stem cells in combination with polycaprolactone/gelatin nanofibrous membranes enhance wound healing by promoting angiogenesis. J Transl Med 2014;274.
35 Guan J, Niu X, Gong FX et al. Biological characteristics of human-urine-derived stem cells: Potential for cell-based therapy in neurology. Tissue Eng Part A 2014;20:1794–1806.
36 Jia B, Chen S, Zhao Z et al. Modeling of hemophilia A using patient-specific induced pluripotent stem cells derived from urine cells. Life Sci 2014;108:22–29.
37 Pel M, U J, Zhang Y et al. Expansion on a matrix deposited by nonchondrogenic urine stem cells strengthens the chondrogenic capacity of repeated-passage bone marrow stromal cells. Cell Tissue Res 2014;356:391–403.
38 Chen Y, Luo R, Xu Y et al. Generation of systemic lupus erythematosus-specific induced pluripotent stem cells from urine. Rheumatol Int 2013;33:2127–2134.
39 Zhou T, Benda C, Dunzinger S et al. Generation of human induced pluripotent stem cells from urine samples. Nat Protoc 2012;7:2080–2089.
40 Benda C, Zhou T, Wang X et al. Urine as a source of stem cells. Adv Biochem Eng Biotechnol 2013:129:19–32.
41 Zhou T, Benda C, Dunzinger S et al. Generation of induced pluripotent stem cells from urine. J Am Soc Nephrol 2011;22:1221–1228.
42 Liu G, Wang X, Sun X et al. The effect of urine-derived stem cells expressing VEGF loaded in collagen hydrogels on myogenesis and innervation following after subcutaneous implantation in nude mice. Biomaterials 2013;34:8617–8629.
43 Lagarkova MA, Volchikov PY, Philenoko ES et al. Efficient differentiation of hESCs into endothelial cells in vitro is secured by epigenetic changes. Cell Cycle 2008;7:2929–2935.
44 Kane NM, Meloni M, Spencer HL et al. Derivation of endothelial cells from human embryonic stem cells by directed differentiation: Analysis of microRNA and angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol 2010;30:1389–1397.
45 Zhang P, Moudgil N, Hager E et al. Endothelial differentiation of adipose-derived stem cells from elderly patients with cardiovascular disease. Stem Cells Dev 2011;20:977–988.
46 Henry TD, Annex BH, McKendall GR et al. The VIVA trial: Vascular endothelial growth factor in ischemic vascular angiogenesis. Circulation 2003;107:1359–1365.
47 Semenza GL. Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med 2003;54:17–28.
48 Van Belle E, Witztenbichler B, Chen D et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: The case for paracrine amplification of angiogenesis. Circulation 1998;97:381–390.
49 Deb A, Davis BH, Guo J et al. SFRP2 regulates cardiomyogenic differentiation by inhibiting a positive transcriptional autoregulatory loop of Wnt3a. Stem Cells 2008;26:35–44.

See www.StemCellsTM.com for supporting information available online.